A Novel prodrug of glutamylcyclotransferase inhibitor has anti-proliferative activity *in vitro* and anti-cancer activity *in vivo*

Hiromi Ii[1], Taku Yoshiya[2],Susumu Nakata[1], Keiko Taniguchi[1], Koushi Hidaka[3], Shugo Tsuda[2], Masayoshi Mochizuki[2], Yuji Nishiuchi2, Yuko Tsuda[3], Kosei Ito[4], Susumu Kageyama[5] and **Tatsuhiro Yoshiki[1,4]**
[1]Kyoto Pharmaceutical University, Japan
[2]Peptide Institute Inc., Japan
[3]Kobe Gakuin University, Japan
[4]Nagasaki University, Japan
[5]Shiga University of Medical Science, Japan

C7 or f24 was discovered as a highly expressed protein in bladder cancers by a proteomic analysis and later identi ed as the α-glutamylcyclotransferase (GGCT). e silencing of GGCT using siRNA inhibited cancer cell proliferation and tumor growth in mice inoculated with cancer cells. However, the relationship between GGCT enzymatic activity and these phenotypes remained unbu42o(n)4 (d (h)4 (eMa3u(n)4 (d (b r)13 (if)9 op)12 (r)13 ().6 (,(w)8 ((t)-5 (t)-6 i(e)-4.9 (d(t)5.1 (r iden)1.11 (t)-5 li ancercellwascioi(r)-6mnedbyHPsedeumonstatedant-poro-7(iif)9er(a)19(t)-5(i)7(v-8(rac)79(t)-5(i)7(v)-3(i)12(t)25.9(m)12(f)-6(h)4(emn)4(t)-6(h239(y

Notes: